Biotechnology News and Research

RSS

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

18 Mar 2010

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

PPD and Southern Research Institute today announced they have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on client bids and projects.

18 Mar 2010

Micromet announces the closing of previously announced underwritten public offering

Micromet, Inc. announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.

18 Mar 2010

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Executives from pharmaceutical companies and health care payer and provider organizations convened at the "Selling Pharmaceuticals in 2015" forum in Philadelphia to discuss mutually beneficial partnerships that, if implemented, could replace the traditional model of selling drugs on price, features and benefits with a new model that focuses on quantifying and communicating total value.

18 Mar 2010

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Enzo Biochem, Inc., a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today a supply and distribution agreement between Enzo Life Sciences and privately-owned Cancer Genetics Inc., a leading producer of nucleic acid products used in genomic research.

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

HST Global announces final negotiations to obtain needed capital to acquire first wellness center

HST Global, Inc., today announced that it is in final negotiations to obtain the needed capital to complete the acquisition of its first wellness center. This infusion of cash will allow HST to complete the wellness center acquisition and provide operating capital.

17 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

China Sky One Medical's 2009 fourth-quarter total revenues up 15.0%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced financial results for the fourth quarter and fiscal year ended December 31, 2009. The Company also announced its earnings guidance for full year 2010.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

17 Mar 2010

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Hospitalization rates for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information was available to doctors prescribing the drug, researchers from Medco Health Solutions, Inc.-- in association with the Medco Research Institute™ -- and Mayo Clinic announced today.

17 Mar 2010

Can preventative vaccines curb the rising numbers of HIV cases?

According to a recent United Nations study, HIV infection rates among high-risk groups such as gays, drug users and sex workers are on the rise around the world.

17 Mar 2010

Biotechnology News and Research

Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

PPD, Southern Research Institute collaborate in pandemic and seasonal influenza vaccine research

Micromet announces the closing of previously announced underwritten public offering

Drug makers convene to discuss new strategies on how to improve patient care and reduce healthcare costs

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

HST Global announces final negotiations to obtain needed capital to acquire first wellness center

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

China Sky One Medical's 2009 fourth-quarter total revenues up 15.0%

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

Finding right balance between high-throughput sequencing and related bioinformatics analysis

Genetic test helps reduce hospitalization rates for heart patients on warfarin

Can preventative vaccines curb the rising numbers of HIV cases?

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News